VistaGen Therapeutics (VTGN) Is A Stock That Oppenheimer Seems to be Very Interested In

May 25, 2018 - By Jacob Falcon

Why Has Oppenheimer Given VistaGen Therapeutics (VTGN) a $6.0000 Price Target

In analysts report issued to investors and clients on Thursday, 24 May, equity analysts at Oppenheimer started coverage for VistaGen Therapeutics (VTGN) shares. The firm has decided to set a Buy rating along with a $6.0000, adding 518.56 % to the target.

The stock decreased 1.69% or $0.02 during the last trading session, reaching $0.97. About 1.14 million shares traded or 188.72% up from the average. VistaGen Therapeutics, Inc. (VTGN) has declined 48.63% since May 25, 2017 and is downtrending. It has underperformed by 60.18% the S&P500.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system disorders. The company has market cap of $22.22 million. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It currently has negative earnings. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells.

More important recent VistaGen Therapeutics, Inc. (NASDAQ:VTGN) news were published by: which released: “VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101” on May 02, 2018, also published article titled: “After-Hours Stock Movers 05/24: (VTGN) (NWY) (CAVM) Higher; (ZOES) (BGSF) (EGHT) Lower (more…)”, published: “VistaGen Therapeutics (VTGN) Granted US Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell …” on May 23, 2018. More interesting news about VistaGen Therapeutics, Inc. (NASDAQ:VTGN) was released by: and their article: “Oppenheimer Feels Positive About VistaGen’s ‘Best-In-Class’ Antidepressant, Sets $6 Target” with publication date: May 24, 2018.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.